Compare Hims and Hers Health Inc (HIMS) vs MasTec Inc (MTZ) Price & Performance

Hims & Hers Health trades at $32.70, down 0.43% on the day, with a bearish technical signal despite bullish moving averages. The company reported $2.35 billion in 2025 revenue but swung to a projected net loss for 2026, with mixed quarterly earnings results. Recent news highlights executive changes and anticipation for Q2 2026 results on August 10, 2026, with analyst sentiment leaning toward a Buy consensus.

The outlook is cautious due to profitability concerns and high valuation multiples, but growth opportunities in weight-loss and telehealth services offer potential. Key risks include execution challenges and regulatory scrutiny. The stock presents a speculative growth play with a consensus price target of $33.57, slightly above the current price.

MasTec (MTZ) trades at $336.61, up 2.13% with strong analyst support (88.9% buy ratings) and a consensus price target of $497.45. The stock shows a bearish technical signal despite recent earnings beats, with Q1 2026 EPS of $1.39 surpassing expectations. The company's $1.65 billion acquisition of Superior Group positions it to capitalize on AI-driven data center infrastructure demand, supported by a record $20.3 billion backlog. Valuation metrics include a P/E of 57.72 and ROE of 14.53%, indicating premium pricing but solid profitability.

Outlook remains positive due to infrastructure spending tailwinds and strategic acquisitions, though high valuation and integration risks from the Superior deal warrant caution. Revenue growth is projected to rise from $14.30 billion in 2025 to $15.30 billion in 2026, with net income margin improving to 2.94%. Key risks include execution challenges and macroeconomic sensitivity, but institutional bullishness suggests upside potential if earnings momentum continues.